{"organizations": [], "uuid": "e8a6f52341f3f383dda9294190d1df491c8cd729", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/impax-labs-lawsuit/impax-reaches-20-mln-deal-to-end-trial-over-generic-drugs-delay-idUSL1N1RB0UW", "country": "US", "domain_rank": 408, "title": "Impax reaches $20 mln deal to end trial over generic drug's delay", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-29T16:50:00.000+03:00", "replies_count": 0, "uuid": "e8a6f52341f3f383dda9294190d1df491c8cd729"}, "author": "", "url": "https://www.reuters.com/article/impax-labs-lawsuit/impax-reaches-20-mln-deal-to-end-trial-over-generic-drugs-delay-idUSL1N1RB0UW", "ord_in_thread": 0, "title": "Impax reaches $20 mln deal to end trial over generic drug's delay", "locations": [], "entities": {"persons": [{"name": "nate raymond", "sentiment": "none"}, {"name": "chizu nomiyama", "sentiment": "none"}], "locations": [{"name": "boston", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}], "organizations": [{"name": "impax", "sentiment": "negative"}, {"name": "impax laboratories inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29, 2018 / 1:51 PM / in 15 minutes Impax reaches $20 mln deal to end trial over generic drug's delay Reuters Staff 1 Min Read \nBOSTON, March 29 (Reuters) - Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn. \nThe accord, disclosed in papers filed in federal court in Boston, brought to an end a rare trial in a class action lawsuit involving an alleged “pay-for-delay” patent litigation settlement between a brand-name drugmaker and a generic company. (Reporting by Nate Raymond in Boston Editing by Chizu Nomiyama)", "external_links": [], "published": "2018-03-29T16:50:00.000+03:00", "crawled": "2018-03-29T17:17:15.000+03:00", "highlightTitle": ""}